atenolol has been researched along with ketanserin in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bartoccini, F; Carminati, P; Castorina, M; Di Cesare, MA; Di Serio, S; Gallo, G; Ghirardi, O; Giorgi, F; Giorgi, L; Minetti, P; Piersanti, G; Tarzia, G; Tinti, MO | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Axe, FU; Bembenek, SD; Butler, CR; Coles, F; Dunford, PJ; Edwards, JP; Fourie, AM; Grice, CA; Karlsson, L; Lundeen, K; Riley, JP; Savall, BM; Tays, KL; Wei, J; Williams, KN; Xue, X | 1 |
| Altenbach, RJ; Brioni, JD; Carr, TL; Chandran, P; Cowart, MD; Esbenshade, TA; Honore, P; Hsieh, GC; Lewis, LG; Liu, H; Manelli, AM; Marsh, KC; Milicic, I; Miller, TR; Strakhova, MI; Vortherms, TA; Wakefield, BD; Wetter, JM; Witte, DG | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K | 1 |
| Colau, D; Dolusić, E; Frédérick, R; Larrieu, P; Masereel, B; Moineaux, L; Pilotte, L; Pochet, L; Stroobant, V; Van den Eynde, B; Wouters, J | 1 |
| Anzini, M; Brogi, S; Butini, S; Campiani, G; Cappelli, A; Caselli, G; Castriconi, F; Gemma, S; Giordani, A; Giorgi, G; Giuliani, G; Lanza, M; Letari, O; Makovec, F; Manini, M; Mennuni, L; Valenti, S | 1 |
| Belyakov, S; Dambrova, M; Kazoka, H; Kuznecovs, J; Lebedev, A; Liepinsh, E; Mishnev, A; Orlova, N; Ponomaryov, Y; Vavers, E; Veinberg, G; Vikainis, S; Vilskersts, R; Vorona, M; Zvejniece, L | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E | 1 |
| Filipek, B; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pańczyk, K; Pękala, E; Rapacz, A; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D; Żesławska, E | 1 |
| Hu, J; Hu, Q; Kong, X; Liu, J; Luo, G; Shen, H; Wang, C; Wu, T; Wu, X; Xiang, Q; Xu, Y; Zhang, C; Zhang, Y; Zhuang, X; Zou, L | 1 |
| Dagnino, F; Ghia, M; Mattioli, F; Mereto, E; Testa, R | 1 |
| Andreoni, A; Antonicelli, R; Gambini, C; Paciaroni, E; Saccomanno, G | 1 |
| Amstein, R; Beretta-Piccoli, C; Bertel, O; Brunner, HR; Bühler, FR; Follath, F; Reutter, F; Vallotton, MB | 1 |
| Amstein, R; Beretta-Piccoli, C; Bertel, O; Brunner, HR; Bühler, FR; Follath, F; Heer, K; Reutter, F; Vallotton, MB | 1 |
| Kirch, W; Ohnhaus, EE | 1 |
| Nagatomo, T; Shibata, A; Shimada, K; Tsuchihashi, H; Wakabayashi, H; Watanabe, K | 1 |
| Bernard, JF; Comet, MA; Hamon, M; Laguzzi, R; Sévoz-Couche, C | 1 |
| Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V | 1 |
1 review(s) available for atenolol and ketanserin
| Article | Year |
|---|---|
Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.
Topics: Abruptio Placentae; Amlodipine; Antihypertensive Agents; Atenolol; Cesarean Section; Chronic Disease; Female; Fetal Growth Retardation; Furosemide; Gestational Age; Humans; Hypertension; Incidence; Infant, Small for Gestational Age; Ketanserin; Methyldopa; Network Meta-Analysis; Nifedipine; Perinatal Death; Pindolol; Pre-Eclampsia; Pregnancy; Pregnancy Complications, Cardiovascular; Premature Birth; Severity of Illness Index | 2020 |
4 trial(s) available for atenolol and ketanserin
| Article | Year |
|---|---|
A double-blind comparative study of ketanserin with atenolol in essential hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Ketanserin; Male; Middle Aged; Randomized Controlled Trials as Topic | 1989 |
[Blood pressure lowering action and tolerance of ketanserin in mono- or combination therapy].
Topics: Adult; Aged; Aged, 80 and over; Amiloride; Atenolol; Blood Pressure; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Ketanserin; Male; Middle Aged | 1989 |
Antihypertensive efficacy and well-being during monotherapy and combination therapy with ketanserin.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atenolol; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Ketanserin; Male; Middle Aged | 1989 |
Double-blind comparison of ketanserin with atenolol: antihypertensive activity and effect on platelet function.
Topics: Adult; Aged; Atenolol; Blood Platelets; Clinical Trials as Topic; Double-Blind Method; Female; Heart Rate; Humans; Ketanserin; Male; Middle Aged; Piperidines; Placebos; Platelet Aggregation | 1986 |
19 other study(ies) available for atenolol and ketanserin
| Article | Year |
|---|---|
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Cell Line; Cricetinae; Cricetulus; Drug Design; Humans; Imidazoles; Male; Models, Molecular; Motor Activity; Purines; Radioligand Assay; Rats; Rats, Inbred F344; Structure-Activity Relationship; Triazoles | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Catalysis; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Magnetic Resonance Spectroscopy; Mice; Structure-Activity Relationship | 2008 |
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperalgesia; Ligands; Mice; Molecular Structure; Pain; Peritonitis; Quinazolines; Rats; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Stereoisomerism; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, Liver; Neuralgia; Nociceptin Receptor; Pyrroles; Rats; Receptors, Opioid; Structure-Activity Relationship | 2010 |
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line; Drug Design; Enzyme Inhibitors; Humans; Immunologic Factors; Indoles; Kinetics; Mice; Neoplasms; Structure-Activity Relationship; Tryptophan Oxygenase | 2011 |
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
Topics: Animals; Area Under Curve; Humans; Intestinal Absorption; Ligands; Male; Metabolic Clearance Rate; Models, Chemical; Models, Molecular; Molecular Structure; Protein Binding; Protein Structure, Tertiary; Pyrrolidinones; Radioligand Assay; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin, 5-HT3; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship | 2013 |
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
Topics: Acetamides; Allosteric Regulation; Animals; Rats; Rats, Wistar; Receptors, sigma; Sigma-1 Receptor; Stereoisomerism; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Male; Mice; Microsomes, Liver; Molecular Structure; Pilocarpine | 2016 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Mice; Models, Molecular; Molecular Structure; Rats; Seizures; Structure-Activity Relationship | 2017 |
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; CREB-Binding Protein; Drug Design; Humans; Indolizidines; Male; Mice; Mice, SCID; Microsomes, Liver; Models, Molecular; Molecular Docking Simulation; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2022 |
Splanchnic haemodynamic effects of ketanserin in anaesthetized cirrhotic rats.
Topics: Animals; Atenolol; Bile Acids and Salts; Blood Pressure; Carbon Tetrachloride; Chenodeoxycholic Acid; Hemodynamics; Ketanserin; Liver Cirrhosis, Experimental; Male; Rats; Rats, Sprague-Dawley; Splanchnic Circulation | 1992 |
Alterations of binding characteristics of alpha 1-,beta 1-adrenoceptors and Ca2+ binding sites in the myocardium of spontaneously hypertensive rats (SHR) by chronically administered bunazosin, atenolol, ketanserin and verapamil.
Topics: Adrenergic alpha-Antagonists; Animals; Atenolol; Binding Sites; Blood Pressure; Calcium Channels; Heart; In Vitro Techniques; Ketanserin; Kinetics; Myocardium; Norepinephrine; Quinazolines; Radioligand Assay; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Verapamil | 1993 |
Cardiac baroreflex facilitation evoked by hypothalamus and prefrontal cortex stimulation: role of the nucleus tractus solitarius 5-HT2A receptors.
Topics: Animals; Atenolol; Atropine Derivatives; Baroreflex; Brain; Electric Stimulation; Fluorobenzenes; Heart; Ketanserin; Male; Microinjections; Neural Inhibition; Neural Pathways; Parasympatholytics; Piperidines; Prefrontal Cortex; Preoptic Area; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Serotonin Antagonists; Solitary Nucleus; Stimulation, Chemical; Sympatholytics | 2006 |